BioSpace News Archive

Galapagos NV announced its first quarter 2024 financial results and provided a business update and outlook for the remainder of 2024.

aTyr Pharma, Inc., a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, announced first quarter 2024 results and provided a corporate update.

QIAGEN announced the availability of QCI Secondary Analysis, a cloud-based software-as-a-services solution enabling high-throughput secondary analysis for use with any clinical next-generation sequencing data.

OrthoPediatrics Corp. announced it has received the “Breakthrough Device” Designation from the Food and Drug Administration for its new eLLi surgical device, an implant designed to address severe pathology associated with Early Onset Scoliosis, which can be associated with thoracic insufficiency, a potentially life-threatening condition.

Cytokinetics, Incorporated announced that on April 30, 2024 it granted stock options to purchase an aggregate of 29,646 shares of common stock and 17,012 shares of restricted stock units convertible into shares of common stock upon vesting to five new employees, whose employment commenced in April 2024, as a material inducement to their employment.

Codexis, Inc., a leading enzyme engineering company, announced financial results for the first quarter ended March 31, 2024, and provided a business update.

Following a trial in January 2023, Canada’s Federal Court has issued a judgment declining to uphold the Canadian patent for Metoject®. Medexus Pharmaceuticals

MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the “Company” or “MustGrow”) is pleased to announce an exclusive distribution agreement (the “Agreement”) with G.S. Long Co

XyloCor Therapeutics Positive EXACT Phase 2 Data for Lead Candidate XC001 Simultaneously Presented at Society for Cardiovascular Angiography & Interventions (SCAI) 2024 Scientific Sessions and Published in Circulation: Cardiovascular Interventions.

The growth in ALK’s overall sales was primarily driven by the European tablet sales, which were boosted by the inflow of new patients and improved pricing.